PHAT Company Profile and Key Details

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) closed at $10.96 USD, gaining $0.11 (1.01%) from the previous close of $10.85. The stock is currently mid-range between its 52-week high and low $2.21 and $18.31. With a market capitalization of about $863.63 million, Phathom Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 1.13 million shares, volume is running light vs its 52-week average. Headquartered in Florham Park, NJ, Phathom Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven L. Basta, the company employs approximately 427 people and listed since October 25, 2019. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

Short-term trend indicators are mixed aligned (SMA20 7.7%, SMA50 -5.89%, SMA200 16.63%). The stock’s 14-day RSI is 54.76 (neutral), while the ATR of 0.94 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.94% below its high and over 513.57% above its low. Average 10-day trading volume of 1.04 million shares is in line with the 3-month average of 1.12 million, indicating normal recent market interest.

Phathom Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.10. This means the shares are trading below this model’s fair value.

Phathom Pharmaceuticals, Inc. generated EPS of -$3.81 over the past year. Five-year average earnings growth is 12.5%. The latest quarter delivered EPS of -$0.41. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$21.16. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $25.00. The high target offers 155.47% upside. The low target suggests 128.1% downside. The mean target is $27.00. This offers 146.35% upside. Phathom Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by 36.67%. The prior quarter beat by 3.95%. Over the last six quarters, Apple has recorded several small beats. These include 4.17% in August 08, 2024.